Skyrizi and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs but through very different mechanisms. Skyrizi is an IL-23 p19-selective biologic that gained UC approval in June 2024. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing its superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or are looking for alternatives to anti-TNF therapy. This guide walks through the skyrizi vs entyvio ulcerative colitis comparison.
IL-23 p19 vs Gut-Selective Mechanism
Skyrizi (risankizumab) binds the p19 subunit of interleukin-23, selectively blocking the Th17-driving cytokine that fuels UC inflammation. Its immune effects are systemic but narrowly focused on IL-23. Entyvio (vedolizumab) binds the alpha-4-beta-7 integrin, a receptor found almost exclusively on gut-homing lymphocytes. By blocking these immune cells from entering inflamed colonic tissue, Entyvio quiets UC inflammation without meaningfully suppressing the immune system elsewhere. The risankizumab vs vedolizumab UC distinction shapes how each drug performs in different patient populations and their long-term safety profiles.
UC Efficacy Data
Skyrizi's UC efficacy rests on INSPIRE (induction) and COMMAND (maintenance), which showed significant improvements over placebo on clinical remission, endoscopic improvement, and steroid-free remission. Entyvio's UC efficacy was established in GEMINI-1 and confirmed in VARSITY, where vedolizumab was directly compared with adalimumab in a head-to-head trial. VARSITY showed Entyvio superior to Humira on clinical remission at 52 weeks (31.3% vs 22.5%), establishing vedolizumab as a strong first-line UC biologic. No head-to-head trial has directly compared Skyrizi with Entyvio in UC. Indirect comparisons suggest similar clinical remission rates, with Skyrizi potentially producing stronger endoscopic outcomes based on class-wide IL-23 data.
Onset of Action
Skyrizi produces clinically meaningful response in UC by week 12, based on INSPIRE. Entyvio's onset is slower, with meaningful response often not evident until week 10 to 14 and continued improvement through week 26. For UC patients with active symptoms who cannot tolerate a long ramp-up, Skyrizi's slightly faster onset is an advantage. For patients in less acute states or those prioritizing the narrowest systemic immune footprint, Entyvio's slower onset is generally manageable with supportive care.
Safety and Infection Risk
Both drugs have favorable safety profiles relative to anti-TNFs. Entyvio's gut-selective action produces very low rates of systemic infection, and its long-term safety data is among the cleanest of any IBD biologic for non-GI infections. A 2024 Swedish registry study flagged a higher rate of serious gastrointestinal infections on vedolizumab compared with anti-TNFs, though overall systemic infection risk was lower. Skyrizi's UC safety data from INSPIRE and COMMAND has been favorable, consistent with its broader Crohn's and psoriasis experience. For skyrizi vs entyvio UC effectiveness and safety, both drugs are attractive to patients concerned about long-term infection risk on anti-TNFs.
Administration and Dosing
Skyrizi for UC uses IV induction at weeks 0, 4, and 8 (1200 mg per infusion), followed by subcutaneous maintenance of 180 mg or 360 mg every 8 weeks. Entyvio starts with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks. After IV induction, Entyvio patients who respond by week 6 can switch to a 108 mg subcutaneous pen every 2 weeks, according to Takeda's dosing information. For UC patients comparing long-term dosing frequency, Skyrizi's every-8-week SC maintenance is less frequent than Entyvio's every-2-weeks SC maintenance after conversion, though Entyvio's IV maintenance (for those who stay on IV) is also every 8 weeks.
Anti-TNF Experienced Patients
For UC patients who have already failed an anti-TNF, both drugs have demonstrated efficacy. INSPIRE included biologic-experienced UC patients and showed meaningful response rates on Skyrizi. Entyvio also has anti-TNF experienced data, with real-world cohorts showing comparable response rates in this population to Stelara or other IL-23 pathway biologics. For patients who have cycled through one anti-TNF and are choosing between Skyrizi and Entyvio, trial data supports both drugs as reasonable second-line options. Your GI will weigh prior biologic exposure pattern, current disease severity, and comorbidities when making the recommendation.
Choosing With Your GI
For a UC patient deciding between Skyrizi and Entyvio, both drugs offer meaningful advantages over anti-TNFs. Skyrizi tends to win on speed of onset, clinical remission rates, and potentially stronger endoscopic outcomes. Entyvio tends to win on the narrowest systemic safety footprint and a head-to-head trial (VARSITY) establishing its superiority over Humira in UC. Your GI will weigh disease severity, prior biologic exposure, comorbidities, and insurance coverage. Before starting either drug, ask how response will be measured after induction (week 12 for Skyrizi, week 14 for Entyvio), what to do if symptoms persist, and whether therapeutic drug monitoring will be part of your plan. A log of stool frequency, urgency, blood, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.